| abstract |
Therapeutic agents comprising β-1,6-D-glucan can be conjugated with targeting moieties, as well as, for example, conjugated methods using these conjugates as therapeutic agents for treating various cancers. be able to. A composition comprising a particular size of β-1,6-D-glucan oligosaccharide may be useful in the preparation of a therapeutic agent. In some embodiments, the oligosaccharide is modified in a manner that allows conjugation with a targeting moiety. Such chemically modified β-1,6-D-glucan can also bind to endogenous anti-β-1,6-D-glucan antibodies, thereby maintaining the desired function. It has been analyzed. The present invention relates to modifications of β-1,6-D-glucan, such as the structure of formula (I), and the ability of these compositions to modulate immune responses. [Selection figure] None |